Shenzhen Chipscreen Biosciences Co., Ltd. (SHA:688321)
China · Delayed Price · Currency is CNY 29.40
-0.13 (-0.44%)
Apr 29, 2026, 9:35 AM CST
SHA:688321 Revenue
In the year 2025, Shenzhen Chipscreen Biosciences had annual revenue of 910.06M CNY with 38.32% growth. Shenzhen Chipscreen Biosciences had revenue of 235.90M in the quarter ending December 31, 2025, with 33.40% growth.
Revenue
910.06M
Revenue Growth
+38.32%
P/S Ratio
14.37
Revenue / Employee
908.25K
Employees
1,002
Market Cap
13.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 910.06M | 252.11M | 38.32% |
| Dec 31, 2024 | 657.95M | 134.24M | 25.63% |
| Dec 31, 2023 | 523.71M | -6.23M | -1.18% |
| Dec 31, 2022 | 529.94M | 99.49M | 23.11% |
| Dec 31, 2021 | 430.45M | 160.98M | 59.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Hisun Pharmaceutical | 10.31B |
| Shanghai Shyndec Pharmaceutical | 9.36B |
| Zhejiang Medicine | 8.82B |
| Guobang Pharma | 6.09B |
| Shenzhen Hepalink Pharmaceutical Group | 5.48B |
| Zhejiang Jiuzhou Pharmaceutical | 5.22B |
| Zhejiang Jingxin Pharmaceutical | 4.00B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.98B |